ANO2 and myeloid sarcoma: Recently, anoctamin-2 has been proposed as an autoimmune target in MS with antibody response associated with higher MS risk, along with cross-reactivity to specific peptides of EBNA-1.30 Finally, the sequence homology between EBNA-1 and GlialCAM has shown potent immune reactivity in MS.32 While the steady increase in MS risk related to EBNA-1 antibody levels is consistent with a direct pathological role of that immunity with the multitude of potential mimicry epitopes, the degree and extent of molecular mimicry in vivo for MS pathogenesis remain to be firmly defined.